IFNG and neoplasm: The phase II DUTRENEO trial prospectively classified patients as having “hot” tumours or “cold” tumours depending on an 18-gene IFN-gamma immune signature (tumour immune score, TIS) and tested durvalumab plus tremelimumab versus chemotherapy in the “hot” tumours.